127 related articles for article (PubMed ID: 37738542)
1. Characterization of the Tumor Microenvironment of De Novo Oligometastatic Breast Cancer in a Nationwide Cohort.
Steenbruggen TG; Wolf DM; Thijssen B; Sanders J; Cornelissen S; Salgado R; Mittempergher L; Bhaskaran R; Broeks A; Lips EH; Siesling S; Sonke GS; Horlings HM; van 't Veer LJ
JCO Precis Oncol; 2023 Sep; 7():e2200670. PubMed ID: 37738542
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer.
Steenbruggen TG; Schaapveld M; Horlings HM; Sanders J; Hogewoning SJ; Lips EH; Vrancken Peeters MT; Kok NF; Wiersma T; Esserman L; van 't Veer LJ; Linn SC; Siesling S; Sonke GS
JNCI Cancer Spectr; 2021 Jun; 5(3):. PubMed ID: 33977227
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors in patients with oligometastatic breast cancer - A systematic review.
van Ommen-Nijhof A; Steenbruggen TG; Schats W; Wiersma T; Horlings HM; Mann R; Koppert L; van Werkhoven E; Sonke GS; Jager A
Cancer Treat Rev; 2020 Dec; 91():102114. PubMed ID: 33161237
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes of oligometastatic breast cancer patients treated with curative intent: an updated report.
Nagasaki E; Kudo R; Tamura M; Hayashi K; Uwagawa T; Kijima Y; Nogi H; Takeyama H; Suzuki M; Nishikawa M; Yano S; Kobayashi T
Breast Cancer; 2021 Sep; 28(5):1051-1061. PubMed ID: 33840010
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance and low tumor-initiating properties of oligometastatic breast cancer in pulmonary metastasectomy.
Mimoto R; Kobayashi T; Imawari Y; Kamio M; Kato K; Nogi H; Toriumi Y; Hirooka S; Uchida K; Takeyama H
Breast Cancer Res Treat; 2014 Sep; 147(2):317-24. PubMed ID: 25156580
[TBL] [Abstract][Full Text] [Related]
6. Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review.
Kobayashi T; Ichiba T; Sakuyama T; Arakawa Y; Nagasaki E; Aiba K; Nogi H; Kawase K; Takeyama H; Toriumi Y; Uchida K; Kobayashi M; Kanehira C; Suzuki M; Ando N; Natori K; Kuraishi Y
Breast Cancer; 2012 Jul; 19(3):218-37. PubMed ID: 22532161
[TBL] [Abstract][Full Text] [Related]
7. Survival and prognostic factors in oligometastatic breast cancer.
van Ommen-Nijhof A; Steenbruggen TG; Capel L; Vergouwen M; Vrancken Peeters MT; Wiersma TG; Sonke GS
Breast; 2023 Feb; 67():14-20. PubMed ID: 36549169
[TBL] [Abstract][Full Text] [Related]
8. Systemic treatment with or without ablative therapies in oligometastatic breast cancer: A single institution analysis of patient outcomes.
Glemarec G; Lacaze JL; Cabarrou B; Aziza R; Jouve E; Zerdoud S; De Maio E; Massabeau C; Loo M; Esteyrie V; Ung M; Dalenc F; Izar F; Chira C
Breast; 2023 Feb; 67():102-109. PubMed ID: 36709639
[TBL] [Abstract][Full Text] [Related]
9. Clinical and pathological characterization of 158 consecutive and unselected oligometastatic breast cancers in a single institution.
Lacaze JL; Chira C; Glemarec G; Monselet N; Cassou-Mounat T; De Maio E; Jouve E; Massabeau C; Brac de la Perrière C; Selmes G; Ung M; Nicolai V; Cabarrou B; Dalenc F
Breast Cancer Res Treat; 2023 Apr; 198(3):463-474. PubMed ID: 36790573
[TBL] [Abstract][Full Text] [Related]
10. Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty.
Bamias A; Stenzl A; Brown SL; Albiges L; Babjuk M; Birtle A; Briganti A; Burger M; Choudhury A; Colecchia M; De Santis M; Fanti S; Fonteyne V; Gallucci M; Rivas JG; Huddart R; Junker K; Kroeze S; Loriot Y; Merseburger A; Montironi R; Necchi A; Oing C; Oldenburg J; Ost P; Pinkawa M; Ribal MJ; Rouprêt M; Thoeny H; Zilli T; Hoskin P
Eur Urol; 2023 Oct; 84(4):381-389. PubMed ID: 37217391
[TBL] [Abstract][Full Text] [Related]
11. SABR in oligometastatic breast cancer: Current status and future directions.
Stewart R; White M; Tan J; Siva S; Karroum L; David S
Breast; 2021 Dec; 60():223-229. PubMed ID: 34739890
[TBL] [Abstract][Full Text] [Related]
12. Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER.
Yardley DA; Tripathy D; Brufsky AM; Rugo HS; Kaufman PA; Mayer M; Magidson J; Yoo B; Quah C; Ulcickas Yood M
Br J Cancer; 2014 May; 110(11):2756-64. PubMed ID: 24743708
[TBL] [Abstract][Full Text] [Related]
13. Oligometastatic breast cancer: An institutional analysis.
Gogia A; S Deo SV; Sharma DN; Mathur S
Indian J Cancer; 2022; 59(2):257-262. PubMed ID: 35946184
[TBL] [Abstract][Full Text] [Related]
14. Long-term Survival Among Patients With De Novo Human Epidermal Growth Receptor 2-Positive Metastatic Breast Cancer in Manitoba.
McAndrew EN; Graham J; Dufault B; Desautels DN; Kim CA
Am J Clin Oncol; 2024 Mar; 47(3):122-127. PubMed ID: 38047455
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.
Wong Y; Raghavendra AS; Hatzis C; Irizarry JP; Vega T; Horowitz N; Barcenas CH; Chavez-MacGregor M; Valero V; Tripathy D; Pusztai L; Murthy RK
Oncologist; 2019 Mar; 24(3):313-318. PubMed ID: 30139836
[TBL] [Abstract][Full Text] [Related]
16. Oligometastatic Breast Cancer: How to Manage It?
Barberi V; Pietragalla A; Franceschini G; Marazzi F; Paris I; Cognetti F; Masetti R; Scambia G; Fabi A
J Pers Med; 2021 Jun; 11(6):. PubMed ID: 34207648
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer.
Harano K; Lei X; Gonzalez-Angulo AM; Murthy RK; Valero V; Mittendorf EA; Ueno NT; Hortobagyi GN; Chavez-MacGregor M
Breast Cancer Res Treat; 2016 Sep; 159(2):367-74. PubMed ID: 27522517
[TBL] [Abstract][Full Text] [Related]
18. Distinct Stromal and Immune Features Collectively Contribute to Long-Term Survival in Pancreatic Cancer.
Sadozai H; Acharjee A; Eppenberger-Castori S; Gloor B; Gruber T; Schenk M; Karamitopoulou E
Front Immunol; 2021; 12():643529. PubMed ID: 33679807
[No Abstract] [Full Text] [Related]
19. Oligometastatic Breast Cancer: Is This a Curable Entity? A Contemporary Review of the Literature.
Makhlin I; Fox K
Curr Oncol Rep; 2020 Feb; 22(2):15. PubMed ID: 32025905
[TBL] [Abstract][Full Text] [Related]
20. Defining Oligometastatic Bladder Cancer: A Systematic Review.
Bamias A; Stenzl A; Zagouri F; Andrikopoulou A; Hoskin P
Eur Urol Open Sci; 2023 Sep; 55():28-37. PubMed ID: 37662704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
